News & Updates
A New mRNA Vaccine Could Help Prevent Skin Cancer from Returning
Tuesday, October 6, 2026
A promising new development in cancer research could change how doctors fight melanoma, one of the most aggressive forms of skin cancer. Moderna and Merck recently announced encouraging results from a Phase 3 clinical trial testing a personalized mRNA treatment designed to help prevent melanoma from returning or spreading after surgery. The treatment uses genetic information from an individual patient’s tumor to create a customized vaccine that trains the immune system to recognize and target cancer cells. The results mark an important milestone for the field of personalized cancer vaccines, with researchers now exploring whether this approach could be applied to other types of cancer.
For Philly Fights Cancer, breakthroughs like this demonstrate the importance of investing in research and clinical trials that can translate scientific discoveries into new possibilities for patients. Our mission is rooted in supporting groundbreaking work at Penn Medicine’s Abramson Cancer Center, where researchers and clinicians are advancing innovative approaches to cancer treatment and care. Robert Vonderheide, MD, DPhil, director of the Abramson Cancer Center, has shared his perspective on the significance of these findings and what they could mean for the future of cancer vaccines. Read more from Dr. Vonderheide and explore the full story at the link.
Share this post
A promising new development in cancer research could change how doctors fight melanoma, one of the most aggressive forms of skin cancer. Moderna and Merck recently announced encouraging results from a Phase 3 clinical trial testing a personalized mRNA treatment designed to help prevent melanoma from returning or spreading after surgery. The treatment uses genetic information from an individual patient’s tumor to create a customized vaccine that trains the immune system to recognize and target cancer cells. The results mark an important milestone for the field of personalized cancer vaccines, with researchers now exploring whether this approach could be applied to other types of cancer.
For Philly Fights Cancer, breakthroughs like this demonstrate the importance of investing in research and clinical trials that can translate scientific discoveries into new possibilities for patients. Our mission is rooted in supporting groundbreaking work at Penn Medicine’s Abramson Cancer Center, where researchers and clinicians are advancing innovative approaches to cancer treatment and care. Robert Vonderheide, MD, DPhil, director of the Abramson Cancer Center, has shared his perspective on the significance of these findings and what they could mean for the future of cancer vaccines. Read more from Dr. Vonderheide and explore the full story at the link.